Posted by Michael Wonder on 28 Jan 2017
EMA recommends two Amgen Humira biosimilars
27 January 2017 - The EMA's CHMP on Thursday recommended eight medicines for approval, including two Amgen biosimilars for AbbVie’s blockbuster Humira (adalimumab).
Amgevita and Solymbic are the first adalimumab biosimilars recommended for approval in the EU. Humira was first authorized in the EU on 8 September 2003.
